Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 26 Melanoma 18 Neoplasm Metastasis 14 Neoplasms 12 Squamous Cell Carcinoma of Head and Neck 10 Recurrence 9 Ovarian Neoplasms 7 Skin Neoplasms 6 Head and Neck Neoplasms 5 Carcinoma, Squamous Cell 5 Carcinoma, Renal Cell 5 Carcinoma, Basal Cell 5 Triple Negative Breast Neoplasms 4 Fallopian Tube Neoplasms 4 Breast Neoplasms 4 Uterine Cervical Neoplasms 3 Urinary Bladder Neoplasms 3 Stomach Neoplasms 3 Prostatic Neoplasms 3 Multiple Myeloma 3 Endometrial Neoplasms 3 Colorectal Neoplasms 3 Colonic Neoplasms 3 Carcinoma, Merkel Cell 3 Adenocarcinoma 3 Sarcoma 2 Pancreatic Neoplasms 2 Lymphoma 2 Lung Neoplasms 2 Glioma 2

Interventions

Rituximab 43 Cyclophosphamide 26 fludarabine 15 ibrutinib 14 Vincristine 11 Prednisone 11 Doxorubicin 11 pirtobrutinib 10 Bendamustine Hydrochloride 10 obinutuzumab 9 polatuzumab vedotin 6 Inotuzumab Ozogamicin 6 tocilizumab 5 pembrolizumab 5 glofitamab 5 Gemcitabine 5 zanubrutinib 4 venetoclax 4 ublituximab 4 Lenalidomide 4 Brentuximab Vedotin 4 Antigens, CD19 4 tazemetostat 3 acalabrutinib 3 Everolimus 3 DTRMWXHS-12 3 veltuzumab 2 sepantronium 2 iberdomide 2 denileukin diftitox 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Lymphoma, B-Cell × cemiplimab × Clear all

NCT02651662 2026-06-02

CLIO-1

Regeneron Pharmaceuticals

Phase 1 Completed

Recurrence, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡